Novartis Begins Review of 70% Stake in Indian Unit, Strategic Options Under Consideration
Novartis (NYSE: NVS) has initiated a review process concerning its 70.68% stake in Novartis India...
NYSE: NVS
FDA Approves Takeda’s Eohilia as First Oral Therapy for Eosinophilic Esophagitis in Patients Aged 11 and Up
The U.S. Food and Drug Administration (FDA) has granted approval to Takeda Pharmaceutical Company (TYO:...
Novartis to Acquire MorphoSys for €2.7 Billion in Strategic Oncology Expansion
Switzerland-based Novartis (NYSE: NVS) has announced a voluntary public takeover offer to acquire Germany-based biopharmaceutical...
Novartis and Fudan University Shanghai Cancer Center Renew Partnership to Drive Precision Cancer Treatments
Novartis (NYSE: NVS), the Swiss pharmaceutical colossus, has renewed its memorandum of understanding with Fudan...
Novartis Sees Robust Growth in Innovative Medicines with 2023 Financials Reflecting a Shift Toward R&D Focus
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, reported a substantial leap in its global sales...
Novartis Lutathera Combo Therapy Shows Significant Progress in GEP-NETs
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced preliminary results from a Phase III study...
Novartis Acquires Calypso Biotech for USD 250 Million to Bolster IL-15 Pipeline
Novartis (NYSE: NVS) has finalized an agreement to acquire Netherlands-based Calypso Biotech, a 2013 spinout...
Cytokinetics Attracts Big Pharma Interest Amid Aficamten’s Phase III Success
Cytokinetics (NASDAQ: CYTK), a specialist in cardiovascular diseases, is reportedly attracting interest from multiple Big...
Alphabet’s Isomorphic Labs Inks Pharma Partnerships with Eli Lilly and Novartis
Isomorphic Labs, a drug discovery company under the umbrella of Google’s parent group Alphabet (NASDAQ:...
International Society for Cell & Gene Therapy Comments on FDA’s CAR-T Investigation
The International Society for Cell & Gene Therapy (ISCT) has published a statement addressing the...
Novartis Strikes Deal with Argo Biopharma for Global Rights to siRNA Drug Candidates
Argo Biopharma, a Shanghai-based developer of small interfering RNA (siRNA) drugs, has secured a licensing...
Novartis to Fully Acquire SanReno Therapeutics to Expand Kidney Drug Portfolio in China
Novartis (NYSE: NVS), a Swiss pharmaceutical giant, has announced plans to acquire the remaining shares...
GenScipt Subsidiary Legend Biotech Finalizes Licensing Deal with Novartis for DLL3 CAR-T Therapies
GenScipt Biotech Corp., a China-based Contract Development and Manufacturing Organization (CDMO) (HKG: 1548), has announced...
FDA Prioritizes Roche’s Xolair for Food Allergy Indication Extension Ahead of Q1 Decision
The U.S. Food and Drug Administration (FDA) has prioritized Roche’s (SWX: ROG) indication extension filing...
Jiangsu Hengrui Pharmaceuticals Wins NMPA Approvals for SLE and Lymphoma Drug Candidates
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has announced that...
Novartis Reports Kisqali Success in Reducing Recurrence Risk in Early Breast Cancer
Novartis (NYSE: NVS) has announced an update on the late-stage trial for its CDK4/6 inhibitor...
Novartis’ Fabhalta Wins FDA Nod as First-in-Class Treatment for Paroxysmal Nocturnal Hemoglobinuria
Swiss pharmaceutical giant Novartis (NYSE: NVS) has secured regulatory approval from the US Food and...
Novartis Invests USD 86.4 Million in New Radiotherapy Facility in China
Swiss pharmaceutical giant Novartis (NYSE: NVS) has invested over 600 million Chinese yuan (approximately USD...
CAR T-Cell Therapy Stocks Plunge as FDA Investigates Cancer Reports Linked to Treatments
Shares of Chimeric Antigen Receptor (CAR) T cell therapy companies plummeted on November 28, 2023,...
Novartis Acquires HDAC6 Inhibitor CKD-510 from CKD Pharmaceutical in a $1.31 Billion Deal
Swiss pharmaceutical major Novartis (NYSE: NVS) announced last week that it has struck a deal...